Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

332
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
332

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

Future oncology (London, England)·2026
Same author

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension.

Pulmonary circulation·2026
Same author

Economic reform can save antibiotic innovation.

Nature·2026
Same author

A Call to Reform Congenital Interventional Cardiology Training: A PICES Community Survey.

Pediatric cardiology·2026
Same author

Spike on a bike: mobile harm reduction in action.

Harm reduction journal·2026
Same author

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Blood advances·2026

Related Experiment Video

Updated: Jul 6, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Approach to High-Risk Multiple Myeloma.

Xiaoyi Chen1, Gaurav Varma1, Faith Davies1

  • 1Center Blood Cancer, Perlmutter Cancer Center, New York University, NYCLangone, Room# 496, Medical Science Building 4th Floor, 540 1st Avenue, New York, NY 10016, USA.

Hematology/Oncology Clinics of North America
|January 9, 2024
PubMed
Summary

Improving outcomes for high-risk myeloma (HRMM) requires understanding its genetic drivers and targeting its biology. While prognosis remains challenging, achieving disease eradication may lead to a cure.

Keywords:
AggressiveBiologyGeneticsGuidanceHigh-riskMyelomaTreatment

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Related Experiment Videos

Last Updated: Jul 6, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • High-risk myeloma (HRMM) presents a significant therapeutic challenge with a generally poor prognosis.
  • Current treatment strategies, including novel immunotherapies, offer improvements but may not overcome the inherent aggressiveness of HRMM.
  • A deeper understanding of the genetic underpinnings of HRMM is crucial for developing more effective therapies.

Purpose of the Study:

  • To highlight the critical need for improved outcomes in high-risk myeloma.
  • To emphasize the importance of elucidating genetic drivers for targeted therapeutic development.
  • To explore the potential for cure through achieving minimal residual disease states in HRMM.

Main Methods:

  • Review of current therapeutic strategies and consensus guidelines for high-risk myeloma.
  • Analysis of the role of genetic drivers in HRMM prognosis.
  • Evaluation of novel immunotherapeutic approaches in the context of HRMM.

Main Results:

  • Despite advances, high-risk myeloma patients often face impaired prognoses.
  • Understanding and targeting specific genetic drivers are essential for therapeutic progress.
  • Novel strategies are being implemented, focusing on consensus guidance and immunotherapy.

Conclusions:

  • Achieving complete disease eradication and minimal disease states offers the potential for cure in high-risk myeloma.
  • Continued research into genetic drivers and novel therapeutic targets is paramount.
  • The next decade aims to significantly improve high-risk myeloma outcomes through biological targeting.